ProKidney
Yahoo Finance • 5 days ago
ProKidney Corp (PROK) Touts Reparencel Therapy for Growth
ProKidney Corp (NASDAQ:PROK) is one of the best healthcare penny stocks to buy now. On September 8, at the Morgan Stanley 23rd Annual Global Healthcare Conference, the company reiterated its focus on the promising cell therapy, Reparencel.... Full story
Yahoo Finance • 13 days ago
Which stocks are experiencing notable movement on Friday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT GCTK [ht... Full story
Yahoo Finance • 14 days ago
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT VNCE [https://www.chartmill.com/stock/quote/VNCE/profile] 113.0% VINCE H... Full story
Yahoo Finance • 29 days ago
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced th... Full story
Yahoo Finance • last month
ProKidney Corp (NASDAQ:PROK) Reports Mixed Q2 2025 Results with Regulatory Progress and Narrower Loss
PROKIDNEY CORP. (NASDAQ:PROK [https://www.chartmill.com/stock/quote/PROK]) REPORTS Q2 2025 RESULTS: MIXED FINANCIALS AND REGULATORY PROGRESS ProKidney Corp., a clinical-stage biotechnology company focused on chronic kidney disease (CKD) t... Full story
Yahoo Finance • last month
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced CKD; FDA also confi... Full story
Yahoo Finance • 2 months ago
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement
ProKidney Corp. (NASDAQ:PROK) is one of the best high-return penny stocks to buy now. On July 16, the company confirmed the completion of its corporate domestication from the Cayman Islands to the state of Delaware. The change of jurisdict... Full story
Yahoo Finance • 2 months ago
ProKidney Secures FDA Alignment On Accelerated Approval Pathway For Rilparencel
(RTTNews) - ProKidney Corp. (PROK) Tuesday said it has secured alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel. The FDA confirmed that the slope of estimated glomerular filtra... Full story
Yahoo Finance • 2 months ago
ProKidney stock falls after FDA alignment on rilparencel approval pathway
Investing.com -- ProKidney Corp. (NASDAQ:PROK) stock initially fell 11% in premarket trading after the company announced alignment with the FDA on the accelerated approval pathway for its kidney disease treatment rilparencel. Shares late... Full story
Yahoo Finance • 2 months ago
FDA confirms eGFR slope as acceptable endpoint for rilparencel approval
WINSTON-SALEM, N.C. - ProKidney Corp. (NASDAQ:PROK), a biotechnology company whose shares have surged over 130% in the past six months according to InvestingPro data, announced Tuesday that the U.S. Food and Drug Administration has confirm... Full story
Yahoo Finance • 2 months ago
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated a... Full story
Yahoo Finance • 3 months ago
Prokidney (PROK) chief regulatory officer Weber sells $312k in stock
Prokidney Corp. (NASDAQ:PROK) Chief Regulatory Officer Darin J. Weber, sold 103,480 shares of Class A Common Stock on July 8, 2025, for $3.02, totaling $312,509. The stock, currently trading at $4.34, has seen remarkable gains with a 544%... Full story
Yahoo Finance • 3 months ago
ProKidney stock surges after Citi raises price target to $9
Investing.com -- ProKidney Corp. (NASDAQ:PROK) stock surged 65% in pre-market trading on Wednesday, building on Tuesday’s massive 515% gain following positive clinical trial data. The latest jump came after Citi analysts raised their pr... Full story
Yahoo Finance • 3 months ago
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced th... Full story
Yahoo Finance • 3 months ago
Noteworthy Tuesday Option Activity: SOUN, ALGT, PROK
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in SoundHound AI Inc (Symbol: SOUN), where a total volume of 360,873 contracts has been traded thus far today, a contract vo... Full story
Yahoo Finance • 3 months ago
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trialIn Group 1 (n=24), kidney function stabilized in patients randomized to receive two ri... Full story
Yahoo Finance • 3 months ago
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced th... Full story
Yahoo Finance • 3 months ago
BofA Securities downgrades ProKidney stock to Underperform on reduced sales outlook
Investing.com - BofA Securities downgraded ProKidney Corp. (NASDAQ:PROK) from Neutral to Underperform on Monday, while significantly reducing its price target from $3.00 to $1.00 per share. According to InvestingPro data, the company’s s... Full story
Yahoo Finance • 6 months ago
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to ex... Full story
Yahoo Finance • last year
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
ProKidney Reported interim REGEN-007 data that demonstrate rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKD Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials Closed $14... Full story
